Market Cap 5.30M
Revenue (ttm) 70,000.00
Net Income (ttm) 400,000.00
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 571.43%
Debt to Equity Ratio 0.78
Volume 7,042
Avg Vol 32,834
Day's Range N/A - N/A
Shares Out 996,000.00
Stochastic %K 72%
Beta 0.54
Analysts Sell
Price Target $36.00

Company Profile

PAVmed Inc. engages in acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precance...

Industry: Medical Devices
Sector: Healthcare
Phone: 917 813 1828
Address:
360 Madison Avenue, 25th Floor, New York, United States
JimmyOcarri
JimmyOcarri Aug. 17 at 7:41 PM
0 · Reply
tds_
tds_ Aug. 17 at 12:07 PM
$PAVM PAVmed Maintained at Buy as Analyst Sees Long-Term Growth Upside; $16 Price Target Reaffirmed https://www.tipranks.com/news/ratings/pavmed-maintained-at-buy-as-analyst-sees-long-term-growth-upside-16-price-target-reaffirmed-ratings-news
1 · Reply
Thegame7000
Thegame7000 Aug. 17 at 11:45 AM
$PAVM yes yes yes! #bolieve, Bo Dallas.
0 · Reply
chuckjackson
chuckjackson Aug. 17 at 9:58 AM
$PAVM $LUCD the situation at pavm looks really bleak. $3.78M cash. Burned $2.68M in Q2. Burned $2.60M in Q1. They have no commercial products and no means to raise cash (except if lucd gets the draft and the stock goes above $6.50). What is Lishan thinking? Why hasn't he resized the company to conserve cash? They enough to fund operations until October. What am I missing? @Tom__Brady @BigJuicy @g3ngar @oaksapollo
2 · Reply
trout290zzaam
trout290zzaam Aug. 14 at 1:22 PM
$PAVM Don't suppose anyone listened to call....Anything exciting that might give them some hope besides LUCD?
1 · Reply
tds_
tds_ Aug. 14 at 12:37 PM
$PAVM re Port-IO "Primary focus right now is on the FDA Pre-submission process, and we expect to submit a meeting request in the fourth quarter. The history has been that the regulatory pathway. Based on our prior engagement with FDA, it was our. Been our expectation that that port I o would be. Subject to the de novo pathway. However, engagements with outside regulatory consultants suggest that the publication of our first in human studies may give us a shot at proceeding to a straight 510. This would create a much shorter timeline and lower capital requirements to get to commercialization."
0 · Reply
tds_
tds_ Aug. 14 at 12:04 PM
$LUCD I know we have some $PAVM holders here still... "Veris accelerated its commercial engagement with OSU-The James while progressing development of its implantable physiological monitor toward FDA submission. Lucid secured an important new commercial coverage policy for EsoGuard while continuing to advance its broader commercial initiatives. And, our relaunched medical device portfolio is on track with PortIO and Octeris progressing toward key milestones." https://ir.pavmed.com/2026-08-14-PAVmed-Provides-Business-Update-and-Reports-Second-Quarter-2026-Financial-Results
1 · Reply
trout290zzaam
trout290zzaam Aug. 14 at 12:02 PM
$PAVM Not sure if this means anything but here it is anyway. https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=320272711&type=PDF&symbol=PAVM&cdn=0fa2272bf6ba8999697a2d48bf178efb&companyName=PAVmed+Inc.&formType=SCHEDULE+13G%2FA&dateFiled=2026-08-13
1 · Reply
tds_
tds_ Aug. 14 at 12:02 PM
$PAVM "Veris accelerated its commercial engagement with OSU-The James while progressing development of its implantable physiological monitor toward FDA submission. Lucid secured an important new commercial coverage policy for EsoGuard while continuing to advance its broader commercial initiatives. And, our relaunched medical device portfolio is on track with PortIO and Octeris progressing toward key milestones." https://ir.pavmed.com/2026-08-14-PAVmed-Provides-Business-Update-and-Reports-Second-Quarter-2026-Financial-Results
0 · Reply
theoptionsplug
theoptionsplug Aug. 14 at 6:28 AM
THINGS TO WATCH, FRIDAY, AUGUST 14TH 👁️ $BMY $RLX $OTLK $PAVM $SPY
0 · Reply
Latest News on PAVM
PAVmed reports Q2 adjusted EPS (27c) vs. ($1.40) last year

2026-08-16T13:31:29.000Z - 3 days ago

PAVmed reports Q2 adjusted EPS (27c) vs. ($1.40) last year


PAVmed Earnings Call Transcript: Q2 2026

Aug 14, 2026, 8:30 AM EDT - 5 days ago

PAVmed Earnings Call Transcript: Q2 2026


PAVmed Quarterly report: Q2 2026

Aug 14, 2026, 8:30 AM EDT - 5 days ago

PAVmed Quarterly report: Q2 2026


PAVmed Earnings release: Q2 2026

Aug 14, 2026, 8:30 AM EDT - 5 days ago

PAVmed Earnings release: Q2 2026


PAVmed Slides: Q2 2026

Aug 14, 2026, 8:30 AM EDT - 5 days ago

PAVmed Slides: Q2 2026


PAVmed trading resumes

2026-07-16T13:50:27.000Z - 4 weeks ago

PAVmed trading resumes


PAVmed trading halted, volatility trading pause

2026-07-16T13:45:28.000Z - 4 weeks ago

PAVmed trading halted, volatility trading pause


PAVmed reports Q1 non-GAAP EPS ($1.17) vs. ($1.97) last year

2026-05-15T13:16:42.000Z - 3 months ago

PAVmed reports Q1 non-GAAP EPS ($1.17) vs. ($1.97) last year


PAVmed Earnings Call Transcript: Q1 2026

May 15, 2026, 8:30 AM EDT - 3 months ago

PAVmed Earnings Call Transcript: Q1 2026


PAVmed Quarterly report: Q1 2026

May 15, 2026, 8:30 AM EDT - 3 months ago

PAVmed Quarterly report: Q1 2026


PAVmed Earnings release: Q1 2026

May 15, 2026, 8:30 AM EDT - 3 months ago

PAVmed Earnings release: Q1 2026


PAVmed Slides: Q1 2026

May 15, 2026, 8:30 AM EDT - 3 months ago

PAVmed Slides: Q1 2026


PAVmed Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 3 months ago

PAVmed Proxy statement: Proxy filing


PAVmed Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 3 months ago

PAVmed Proxy statement: Proxy filing


PAVmed Registration statement: Registration filing

Apr 21, 2026, 8:00 AM EDT - 4 months ago

PAVmed Registration statement: Registration filing


PAVmed files to sell 9.23M shares of common stock for holders

2026-04-21T10:05:12.000Z - 4 months ago

PAVmed files to sell 9.23M shares of common stock for holders


PAVmed price target lowered to $16 from $60 at Maxim

2026-03-31T13:35:59.000Z - 5 months ago

PAVmed price target lowered to $16 from $60 at Maxim


PAVmed price target lowered to $16 from $60 at Maxim

2026-03-31T13:28:31.000Z - 5 months ago

PAVmed price target lowered to $16 from $60 at Maxim


PAVmed Earnings Call Transcript: Q4 2025

Mar 30, 2026, 8:30 AM EDT - 5 months ago

PAVmed Earnings Call Transcript: Q4 2025


PAVmed Earnings release: Q4 2025

Mar 30, 2026, 8:30 AM EDT - 5 months ago

PAVmed Earnings release: Q4 2025


PAVmed Annual report: Q4 2025

Mar 30, 2026, 8:30 AM EDT - 5 months ago

PAVmed Annual report: Q4 2025


PAVmed Slides: Q4 2025

Mar 30, 2026, 8:30 AM EDT - 5 months ago

PAVmed Slides: Q4 2025


PAVmed Proxy statement: Proxy Filing

Feb 24, 2026, 7:00 AM EST - 6 months ago

PAVmed Proxy statement: Proxy Filing


PAVmed Proxy statement: Proxy Filing

Feb 13, 2026, 7:00 AM EST - 6 months ago

PAVmed Proxy statement: Proxy Filing


PAVmed trading resumes

2026-02-02T14:45:30.000Z - 7 months ago

PAVmed trading resumes


PAVmed trading halted, volatility trading pause

2026-02-02T14:40:49.000Z - 7 months ago

PAVmed trading halted, volatility trading pause


PAVmed trading resumes

2026-01-21T14:45:24.000Z - 7 months ago

PAVmed trading resumes


PAVmed trading halted, volatility trading pause

2026-01-21T14:40:50.000Z - 7 months ago

PAVmed trading halted, volatility trading pause


Huge Win for PAVmed (PAVM) Sends Shares Surging

2026-01-21T14:36:25.000Z - 7 months ago

Huge Win for PAVmed (PAVM) Sends Shares Surging


PAVmed trading halted, news pending

2026-01-01T00:50:31.000Z - 8 months ago

PAVmed trading halted, news pending


PAVmed announces 1-for-30 reverse stock split

2025-12-30T14:10:18.000Z - 8 months ago

PAVmed announces 1-for-30 reverse stock split


PAVmed Announces Reverse Stock Split

Dec 30, 2025, 9:01 AM EST - 8 months ago

PAVmed Announces Reverse Stock Split


PAVmed Earnings Call Transcript: Q3 2025

Nov 13, 2025, 8:30 AM EST - 9 months ago

PAVmed Earnings Call Transcript: Q3 2025


PAVmed Earnings release: Q3 2025

Nov 13, 2025, 8:30 AM EST - 9 months ago

PAVmed Earnings release: Q3 2025


PAVmed Quarterly report: Q3 2025

Nov 13, 2025, 8:30 AM EST - 9 months ago

PAVmed Quarterly report: Q3 2025


PAVmed Slides: Q3 2025

Nov 13, 2025, 8:30 AM EST - 9 months ago

PAVmed Slides: Q3 2025


PAVmed Proxy statement: Proxy Filing

Oct 31, 2025, 8:00 AM EDT - 10 months ago

PAVmed Proxy statement: Proxy Filing


PAVmed Proxy statement: Proxy Filing

Oct 20, 2025, 8:00 AM EDT - 10 months ago

PAVmed Proxy statement: Proxy Filing


PAVmed Earnings Call Transcript: Q2 2025

Aug 13, 2025, 8:30 AM EDT - 1 year ago

PAVmed Earnings Call Transcript: Q2 2025


PAVmed Earnings release: Q2 2025

Aug 13, 2025, 8:30 AM EDT - 1 year ago

PAVmed Earnings release: Q2 2025


PAVmed Quarterly report: Q2 2025

Aug 13, 2025, 8:30 AM EDT - 1 year ago

PAVmed Quarterly report: Q2 2025


PAVmed Slides: Q2 2025

Aug 13, 2025, 8:30 AM EDT - 1 year ago

PAVmed Slides: Q2 2025


PAVmed Earnings Call Transcript: Q1 2025

May 15, 2025, 8:30 AM EDT - 1 year ago

PAVmed Earnings Call Transcript: Q1 2025


PAVmed Earnings release: Q1 2025

May 15, 2025, 8:30 AM EDT - 1 year ago

PAVmed Earnings release: Q1 2025


PAVmed Quarterly report: Q1 2025

May 15, 2025, 8:30 AM EDT - 1 year ago

PAVmed Quarterly report: Q1 2025


PAVmed Slides: Q1 2025

May 15, 2025, 8:30 AM EDT - 1 year ago

PAVmed Slides: Q1 2025


JimmyOcarri
JimmyOcarri Aug. 17 at 7:41 PM
0 · Reply
tds_
tds_ Aug. 17 at 12:07 PM
$PAVM PAVmed Maintained at Buy as Analyst Sees Long-Term Growth Upside; $16 Price Target Reaffirmed https://www.tipranks.com/news/ratings/pavmed-maintained-at-buy-as-analyst-sees-long-term-growth-upside-16-price-target-reaffirmed-ratings-news
1 · Reply
Thegame7000
Thegame7000 Aug. 17 at 11:45 AM
$PAVM yes yes yes! #bolieve, Bo Dallas.
0 · Reply
chuckjackson
chuckjackson Aug. 17 at 9:58 AM
$PAVM $LUCD the situation at pavm looks really bleak. $3.78M cash. Burned $2.68M in Q2. Burned $2.60M in Q1. They have no commercial products and no means to raise cash (except if lucd gets the draft and the stock goes above $6.50). What is Lishan thinking? Why hasn't he resized the company to conserve cash? They enough to fund operations until October. What am I missing? @Tom__Brady @BigJuicy @g3ngar @oaksapollo
2 · Reply
trout290zzaam
trout290zzaam Aug. 14 at 1:22 PM
$PAVM Don't suppose anyone listened to call....Anything exciting that might give them some hope besides LUCD?
1 · Reply
tds_
tds_ Aug. 14 at 12:37 PM
$PAVM re Port-IO "Primary focus right now is on the FDA Pre-submission process, and we expect to submit a meeting request in the fourth quarter. The history has been that the regulatory pathway. Based on our prior engagement with FDA, it was our. Been our expectation that that port I o would be. Subject to the de novo pathway. However, engagements with outside regulatory consultants suggest that the publication of our first in human studies may give us a shot at proceeding to a straight 510. This would create a much shorter timeline and lower capital requirements to get to commercialization."
0 · Reply
tds_
tds_ Aug. 14 at 12:04 PM
$LUCD I know we have some $PAVM holders here still... "Veris accelerated its commercial engagement with OSU-The James while progressing development of its implantable physiological monitor toward FDA submission. Lucid secured an important new commercial coverage policy for EsoGuard while continuing to advance its broader commercial initiatives. And, our relaunched medical device portfolio is on track with PortIO and Octeris progressing toward key milestones." https://ir.pavmed.com/2026-08-14-PAVmed-Provides-Business-Update-and-Reports-Second-Quarter-2026-Financial-Results
1 · Reply
trout290zzaam
trout290zzaam Aug. 14 at 12:02 PM
$PAVM Not sure if this means anything but here it is anyway. https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=320272711&type=PDF&symbol=PAVM&cdn=0fa2272bf6ba8999697a2d48bf178efb&companyName=PAVmed+Inc.&formType=SCHEDULE+13G%2FA&dateFiled=2026-08-13
1 · Reply
tds_
tds_ Aug. 14 at 12:02 PM
$PAVM "Veris accelerated its commercial engagement with OSU-The James while progressing development of its implantable physiological monitor toward FDA submission. Lucid secured an important new commercial coverage policy for EsoGuard while continuing to advance its broader commercial initiatives. And, our relaunched medical device portfolio is on track with PortIO and Octeris progressing toward key milestones." https://ir.pavmed.com/2026-08-14-PAVmed-Provides-Business-Update-and-Reports-Second-Quarter-2026-Financial-Results
0 · Reply
theoptionsplug
theoptionsplug Aug. 14 at 6:28 AM
THINGS TO WATCH, FRIDAY, AUGUST 14TH 👁️ $BMY $RLX $OTLK $PAVM $SPY
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Aug. 13 at 10:32 PM
$PAVM Q2 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.87 up 96.06% YoY • Reported revenue of $0.03M up 450.00% YoY
0 · Reply
Synaptric
Synaptric Aug. 13 at 8:29 PM
Tomorrow morning's earnings list has no Tech but plenty of Biotech and Medical Devices should be interesting. $QNRX in the Extremely Bullish zone after beginning Neutral. $OTLK in the Bearish zone after beginning the period in Extremely Bullish zone. $TMS downwardly sloped past few days to sit a the lowest sentiment. Nothing is in the Neutral zone. $LFWD $PAVM
0 · Reply
tds_
tds_ Aug. 13 at 6:05 PM
$PAVM volume really picking up the past 3 sessions.
0 · Reply
cwork
cwork Aug. 13 at 5:02 PM
$LUCD $PAVM 💯💯💯
0 · Reply
Quantumup
Quantumup Aug. 13 at 3:28 PM
Needham reiterated $LUCD Buy-$3 and said We Think It's Very Likely That CMS Will Issue A Draft Local Coverage Determination (LCD) Covering EsoGuard This Year. $CSTL MDT MYGN GRAL GH $PAVM NTRA Here's what else Needham said in its note to investors: In 2Q26, EsoGuard test volume grew 1% Y/Y to 2,770. LUCD's 2Q26 revenue came in above consensus and its operating expenses were below our estimate. LUCD ended 2Q26 with ~$33M of cash as its cash burn decreased moderately from 1Q26. Given LUCD's published data and positive Contractor Advisory Committee (CAC) Meeting on 9/4/25, we think it's very likely that CMS will issue a draft Local Coverage Determination (LCD) covering EsoGuard this year. We expect LUCD's revenue growth to increase and to narrow the gap with EsoGuard test volume growth as it gains coverage from Medicare and other insurers, and we reiterate our Buy rating.
1 · Reply
BigJuicy
BigJuicy Aug. 13 at 12:24 PM
$LUCD you can’t make this shit up… still NO draft LCD omggggggg $PAVM
0 · Reply
Thegame7000
Thegame7000 Aug. 13 at 11:42 AM
0 · Reply
dmc4321
dmc4321 Aug. 12 at 2:48 AM
$LUCD If you look at LUCD through the lens of verifiable facts then it all becomes clear. They can not sell. They have failed all 5 times they have tried. If Lishan and Dennis want their roughly $2M package EACH ANNUALLY they need it to be broken across two companies, because $PAVM does nothing. If you have meager sales of a couple of millions a quarter it's embarrassing. But Lishan and Dennis INDIVIDUALLY are paid MULTIPLES EVERY MONTH of what PAVM's ANNUAL Revenue is. If you take Lishan, Dennis and Shaun O'Neill that is a fully loaded cost of over $6M annually. That is more than LUCD's Revenues. The VERY FAT & HAPPY not so LITTLE PIGGIES will feast on retail investors cash for as long as you let them. Think of it over 5 years that's $30M for what progress? Actual measurable progress. NONE. Speak to even one achievements or milestone they themselves set that involves selling or marketing that they have met The ones they can meet is when they pay someone to do something
0 · Reply
g3ngar
g3ngar Aug. 11 at 7:40 PM
0 · Reply
BigJuicy
BigJuicy Aug. 10 at 11:58 PM
$LUCD $PAVM if the LCD isn’t released by 8/31 I’m going to lose my mind.
1 · Reply
BigJuicy
BigJuicy Aug. 10 at 10:51 PM
$PAVM .02 cents soon I guesss I’ll have another massive capital loss
0 · Reply
traderjoe2018
traderjoe2018 Aug. 7 at 11:55 PM
$PAVM how about that relaunched medical device portfolio? How about veris? Not a single damn PR this year about anything substantial here with PAVM. This company is trash.
2 · Reply